Anti-Gal-9 antibody in combination with an agonist antibody to the T cell co-stimulatory receptor GITR (glucocorticoid-induced tumor necrosis factor receptor-related protein) significantly outperforms monotherapy with either agent in suppressing tumor growth and improving survival in the mouse models of colon cancer and TNBC 8. Here, LGALS9 is linked to neoplasm.